DK1740197T3 - Prolyl-endopeptidease (PEP) og glutamin-endoprotease til behandlingen af cøliaki - Google Patents

Prolyl-endopeptidease (PEP) og glutamin-endoprotease til behandlingen af cøliaki

Info

Publication number
DK1740197T3
DK1740197T3 DK05714080.8T DK05714080T DK1740197T3 DK 1740197 T3 DK1740197 T3 DK 1740197T3 DK 05714080 T DK05714080 T DK 05714080T DK 1740197 T3 DK1740197 T3 DK 1740197T3
Authority
DK
Denmark
Prior art keywords
endopeptidease
prolyl
pep
treatment
celiac disease
Prior art date
Application number
DK05714080.8T
Other languages
English (en)
Inventor
Lu Shan
Michael Bethune
Chaitan Khosla
Jonathan Gass
Original Assignee
Alvine Pharmaceuticals Inc
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alvine Pharmaceuticals Inc, Univ Leland Stanford Junior filed Critical Alvine Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1740197T3 publication Critical patent/DK1740197T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK05714080.8T 2004-04-26 2005-02-23 Prolyl-endopeptidease (PEP) og glutamin-endoprotease til behandlingen af cøliaki DK1740197T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56566804P 2004-04-26 2004-04-26
US10/969,314 US7320788B2 (en) 2002-02-14 2004-10-19 Enzyme treatment of foodstuffs for Celiac Sprue
PCT/US2005/006129 WO2005107786A1 (en) 2004-04-26 2005-02-23 Therapeutic enzyme formulations and uses thereof

Publications (1)

Publication Number Publication Date
DK1740197T3 true DK1740197T3 (da) 2013-11-11

Family

ID=35320040

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05714080.8T DK1740197T3 (da) 2004-04-26 2005-02-23 Prolyl-endopeptidease (PEP) og glutamin-endoprotease til behandlingen af cøliaki

Country Status (11)

Country Link
US (1) US7320788B2 (da)
EP (1) EP1740197B1 (da)
JP (3) JP2007534752A (da)
AU (1) AU2005239985B2 (da)
CA (1) CA2563505C (da)
DK (1) DK1740197T3 (da)
ES (1) ES2437569T3 (da)
NO (1) NO340598B1 (da)
PL (1) PL1740197T3 (da)
PT (1) PT1740197E (da)
WO (1) WO2005107786A1 (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003215272B2 (en) * 2002-02-14 2008-04-03 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US8143210B2 (en) * 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
AU2003234634A1 (en) * 2002-05-14 2003-12-02 Felix Hausch Drug therapy for celiac sprue
US7776545B2 (en) * 2002-11-20 2010-08-17 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for Celiac Sprue
GB0212885D0 (en) * 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
US7579313B2 (en) * 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
AU2005237287B2 (en) 2004-04-28 2011-08-11 Btg International Limited Epitopes related to coeliac disease
IL161886A0 (en) * 2004-05-09 2005-11-20 Technion Res & Dev Foundation Development of inducers of udp-n-acetyl-alphad-galactosamine: polypeptide n-acetylgalactosami-nyltransferase 3(ppgantase
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
EP1949093A2 (en) * 2005-10-11 2008-07-30 Alvine Pharmaceuticals, Inc. Compositions and methods for enhanced gastrointestinal stability of oligopeptides and polypeptides
JP2009511040A (ja) 2005-10-11 2009-03-19 モフィン エス．アール．エル． セリアック病患者のための、グルテンを含まない、ブルーベインの（ｂｌｕｅ−ｖｅｉｎｅｄ）日用製品
WO2008115428A2 (en) * 2007-03-16 2008-09-25 The Board Of Trustees Of The Leland Stanford Junior University A scaleable manufacturing process for cysteine endoprotease b, isoform 2
WO2008115411A1 (en) * 2007-03-16 2008-09-25 The Board Of Trustees Of The Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
EP2229404A4 (en) * 2007-12-10 2011-03-09 Univ Leland Stanford Junior ENZYMATIC POLYTHERAPY FOR GASTRIC DIGESTION OF FOOD GLUTEN IN PATIENTS WITH CELIAC DISEASE
ES2343499B1 (es) * 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
AU2009283157B2 (en) * 2008-08-21 2015-02-26 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
JP2012505211A (ja) * 2008-10-10 2012-03-01 アルヴィン ファーマシューティカルズ インコーポレーティッド チモーゲンの迅速な活性化を促進する剤形
HUE027237T2 (en) 2008-11-30 2016-10-28 Immusant Inc Compositions and methods for treatment of celiac disease
AU2010205890B2 (en) * 2009-01-15 2015-01-15 Glutagen Pty Ltd Compositions for the treatment of gluten intolerance and uses thereof
DE102009045268A1 (de) 2009-10-01 2011-04-07 Charité - Universitätsmedizin Berlin Neue Marker für die Diagnose von Zöliakie
US8685392B2 (en) 2009-10-07 2014-04-01 Trustees Of Boston University Rothia species glutamine endopeptidases and use thereof
EP2531521B1 (en) * 2010-02-02 2017-09-06 Amano Enzyme USA., Ltd. Use of proteases for gluten intolerance
CN103097513B (zh) * 2010-03-12 2018-01-30 热尔韦·达诺尼公司 用于乳糜泻的乳酸菌
US9598684B2 (en) 2010-07-07 2017-03-21 Trustees Of Boston University Rothia species gluten-degrading enzymes and uses thereof
CN107831318B (zh) * 2011-01-20 2021-06-18 西瑞斯实验室有限公司 检测谷蛋白敏感性和其区分于乳糜泻的方法和装置
WO2012135646A2 (en) * 2011-03-30 2012-10-04 Alvine Pharmaceuticals, Inc. Proteases for degrading gluten
WO2013016427A1 (en) 2011-07-25 2013-01-31 Alvine Pharmaceuticals, Inc. Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance
CA2882502A1 (en) 2011-08-10 2013-02-14 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
US20140219982A1 (en) * 2011-09-29 2014-08-07 Amano Enzyme Inc. Exogenous opioid peptide-degrading enzyme
ES2595500T3 (es) 2011-12-06 2016-12-30 Fondazione Istituto Insubrico Di Ricerca Per La Vita Nuevas proteasas que pueden hidrolizar péptidos y proteínas de gluten a un pH ácido, procedentes del actinomiceto Actinoallomurus
WO2014011662A2 (en) * 2012-07-09 2014-01-16 Alvine Pharmaceuticals, Inc. Acid stable prolyl endopeptidases for degrading gluten
ITRM20120468A1 (it) * 2012-10-02 2014-04-03 Uni Degli Studi Di Foggia Metodo per la detossificazione delle proteine del glutine dalla granella dei cereali
US9005610B2 (en) * 2012-11-21 2015-04-14 Nepetx, Llc Treatment of gluten intolerance and related conditions
EP2948170B1 (en) 2013-01-23 2020-08-19 Alvine Pharmaceuticals, Inc. Pharmaceutical compositions for treating celiac disease and gluten intolerance
US10266815B2 (en) 2013-08-14 2019-04-23 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
CA2923822A1 (en) 2013-09-10 2015-03-19 Immusant, Inc. Dosage of a gluten peptide composition
EP2883458A1 (en) * 2013-12-11 2015-06-17 DSM IP Assets B.V. Medicament and method for treating innate immune response diseases
PT3139961T (pt) * 2014-05-07 2018-07-13 Nemysis Ltd Hidrogéis de derivados metacrílicos de ácido hialurónico para terapia enzimática oral na doença celíaca
WO2015192211A1 (en) 2014-06-16 2015-12-23 Nepetx, Llc Compositions and methods for treating gluten intolerance and disorders arising therefrom
CA2962933A1 (en) 2014-09-29 2016-04-07 Immusant, Inc. Use of hla genetic status to assess or select treatment of celiac disease
FR3034307B1 (fr) 2015-04-03 2021-10-22 Univ Grenoble 1 Reacteur intestinal implantable
NZ737500A (en) 2015-06-08 2025-02-28 Univ Washington Compositions and methods for treating celiac sprue disease
US10857214B2 (en) 2015-12-16 2020-12-08 Codexis, Inc. Compositions and methods for treating gluten intolerance and disorders arising therefrom
US20190307860A1 (en) 2016-11-23 2019-10-10 Immunogenics Llc Latiglutenase (alv003) for use in the treatment of symptomatic celiac disease, gluten intolerance or gluten sensitivity
WO2020087017A1 (en) * 2018-10-26 2020-04-30 The Regents Of The University Of California Use of proteolytic enzymes to enhance protein bioavailability
KR102184812B1 (ko) * 2018-12-13 2020-11-30 대한민국 새찰쌀보리 추출물을 포함하는 골다공증 예방 또는 치료용 조성물
JP7390398B2 (ja) * 2019-04-02 2023-12-01 サミ－サビンサ グループ リミテッド グルテン不耐性の治療管理のための方法および組成物
JP2022542835A (ja) 2019-07-25 2022-10-07 ネミシス リミテッド 組換えエンドペプチダーゼを含む酵素組成物の製造方法
IT201900012942A1 (it) 2019-07-25 2021-01-25 Nemysis Ltd Metodo per la produzione di una composizione enzimatica comprendente una endopeptidasi ricombinante
EP4469075A4 (en) 2022-01-26 2025-09-10 Digestiva Inc METHODS AND COMPOSITIONS FOR STABILIZING BLOOD GLUCOSE
CN116004751B (zh) * 2022-12-13 2026-02-10 江南大学 一种利用生姜提取液和谷朊粉制备功能性肽的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203967A (en) * 1977-01-13 1980-05-20 Hoffmann-La Roche Inc. Diagnostic test for malabsorption
AU6916694A (en) 1993-05-19 1994-12-12 Cytel Corporation Novel treatments for allergic diseases
US6197356B1 (en) 1993-08-03 2001-03-06 Immunopath Profile, Inc. Process for preparing hypoallergenic foods
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
DE19630557C2 (de) 1996-07-18 1998-07-02 Schuppan Detlef Priv Doz Dr Dr Verfahren zum Nachweis von Antikörpern aus Körperflüssigkeiten durch eine Immunreaktion mit Gewebe-Transglutaminase (tTG) sowie die Verwendung von tTG in Diagnose und Therapie
EP0905518A1 (en) 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptides specific for gluten-sensitive T-cells and use thereof
RS50069B (sr) 1997-12-31 2009-01-22 Pfizer Products Inc., Aril kondenzovana azapoliciklična jedinjenja
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
US6667160B2 (en) 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
ATE475324T1 (de) * 2000-12-07 2010-08-15 Dsm Ip Assets Bv Mit carboxy-terminal prolin peptide angereicherte proteinhydrolysate
AU2003215272B2 (en) 2002-02-14 2008-04-03 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue

Also Published As

Publication number Publication date
AU2005239985A1 (en) 2005-11-17
EP1740197A1 (en) 2007-01-10
NO340598B1 (no) 2017-05-15
EP1740197A4 (en) 2009-09-16
CA2563505A1 (en) 2005-11-17
JP2015063554A (ja) 2015-04-09
ES2437569T3 (es) 2014-01-13
EP1740197B1 (en) 2013-10-16
US20050249719A1 (en) 2005-11-10
WO2005107786A1 (en) 2005-11-17
JP2012092125A (ja) 2012-05-17
US7320788B2 (en) 2008-01-22
JP2007534752A (ja) 2007-11-29
AU2005239985B2 (en) 2010-08-12
PT1740197E (pt) 2013-12-02
PL1740197T3 (pl) 2014-03-31
CA2563505C (en) 2020-09-08
NO20065195L (no) 2007-01-18

Similar Documents

Publication Publication Date Title
DK1740197T3 (da) Prolyl-endopeptidease (PEP) og glutamin-endoprotease til behandlingen af cøliaki
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1830838T3 (da) Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK1951866T3 (da) Delta-9-elongaser og anvendelse heraf til fremstilling af flerumættede fedtsyrer
DK2952178T3 (da) Oftalmiske sammensætninger og fremgangsmåder til behandling af øjne
DK1824470T3 (da) Fremgangsmåde til forlængelse af levetiden og forsinke starttidspunktet for alders-relateret sygdom
DK2084151T3 (da) Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
DK2508521T4 (da) Dimaleat af en aminocrotonylforbindelse og fremgangsmåde til fremstilling deraf
DK3805248T3 (da) Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf
DK2072051T3 (da) Kombination af azelastin og mometason
DK1913157T3 (da) EGFR og KRAS mutationer til forudsigelse af patientrespons for EGFR inhibitorbehandling
DK1942898T3 (da) Dipeptidylpeptidase-inhibitorer til behandling af diabetes
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
DK1771201T3 (da) Sammensætninger og fremgangsmåder til behandling eller forebyggelse af oxalat-relateret sygdom
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1922309T3 (da) N-phenyl-2-pyrimidin-aminderivater og fremgangsmåde til fremstillingen deraf
DK1802749T3 (da) KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser
DK1599469T3 (da) Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed
DK1589973T4 (da) Formulering og fremgangsmåder til behandling af thrombocytæmi
DK1743101T3 (da) Centrifugalpumpe og fremgangsm de til fremstilling af samme
IS7572A (is) Aðferð og efni til lækninga